Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter Syndrome)

Journal of Inherited Metabolic Disease

Volumn 33, Issue SUPPL. 3, 2010, Pages

  Davison, James E ^a,b   Hendriksz, Christian J ^a   Sun, Yu ^a,b   Davies, Nigel P ^a,b   Gissen, Paul ^a,b   Peet, Andrew C ^a,b  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BIOLOGICAL MARKER; CHOLINE; GLUTAMIC ACID; IDURONATE 2 SULFATASE; INOSITOL; N-ACETYLASPARTATE; DRUG DERIVATIVE; N ACETYLASPARTIC ACID;

ADOLESCENT; ANALOGS AND DERIVATIVES; BASAL GANGLION; BRAIN; CASE CONTROL STUDY; CHILD; DISEASE COURSE; ENZYME REPLACEMENT; ENZYMOLOGY; HUMAN; MALE; METABOLISM; MUCOPOLYSACCHARIDOSIS II; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; TREATMENT OUTCOME; ARTICLE; HUNTER SYNDROME;

ADOLESCENT; ASPARTIC ACID; BASAL GANGLIA; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHOLINE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; GLUTAMIC ACID; HUMANS; IDURONATE SULFATASE; INOSITOL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MUCOPOLYSACCHARIDOSIS II; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84897920741     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9197-0     Document Type: Article

References (14)

1. Al Sawaf S, Mayatepek E, Hoffmann B (2008) Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis 31:473-480
2. Griffin JL, Shockcor JP (2004) Metabolic profiles of cancer cells. Nat Rev Cancer 4:551-561
3. Griffin JL, Bollard M, Nicholson JK, Bhakoo K (2002) Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed 15:375-384
4. Hamano K, Hayashi M, Shioda K et al. (2008) Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol 115:547-559
5. Jones SA, Almassy Z, Beck M et al. (2009) Mortality and cause of death in mucopolysaccharidosis type II-A historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 32:534-543
6. Marino S, Borsini W, Buchner S et al. (2006) Diffuse structural and metabolic brain changes in Fabry disease. J Neurol 253:434-440
7. Muenzer J, Wraith JE, Beck M et al. (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465-473
8. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100:1902-1907
9. Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14:260-264
10. Seto T, Kono K, Morimoto K et al. (2001) Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol 50:79-92
11. Tedeschi G, Bonavita S, Banerjee TK, Virta A, Schiffmann R (1999) Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 52:1663-1667
12. Vedolin L, Schwartz IV, Komlos M et al. (2007a) Brain MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical findings. Neurology 69:917-924
13. Vedolin L, Schwartz IV, Komlos M et al. (2007b) Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II. Am J Neuroradiol 28:1029-1033
14. Walkley SU (2009) Pathogenic cascades in lysosomal disease-Why so complex? J Inherit Metab Dis 32:181-189